DSP-2230 is a potent and selective small molecule inhibitor targeting the voltage-gated sodium channels Nav1.7 and Nav1.8. Its mechanism supports its use in preclinical research for investigating pain pathways, including in vitro electrophysiology studies and in vivo models of neuropathic and inflammatory pain.
